Analyst Price Targets — ABT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 13, 2026 9:38 am | — | Wolfe Research | $130.00 | $110.92 | TheFly | Abbott upgraded to Outperform from Peer Perform at Wolfe Research |
| July 28, 2026 12:11 pm | Patrick Wood | UBS | $125.00 | $108.84 | TheFly | Abbott price target lowered to $125 from $135 at UBS |
| July 20, 2026 11:26 am | — | Benchmark Co. | $120.00 | $100.67 | StreetInsider | Abbott Labs (ABT) Reiterated at Buy by Benchmark After Q2 Model Updates |
| July 17, 2026 11:06 am | — | Piper Sandler | $118.00 | $98.82 | TheFly | Abbott price target raised to $118 from $115 at Piper Sandler |
| July 16, 2026 8:00 pm | — | BTIG | $134.00 | $98.82 | StreetInsider | Abbott Labs (ABT) PT Raised to $134 at BTIGMember Login |
| July 6, 2026 12:39 pm | Vijay Kumar | Evercore ISI | $112.00 | $93.64 | TheFly | Abbott price target lowered to $112 from $120 at Evercore ISI |
| June 30, 2026 8:18 pm | David Rescott | Robert W. Baird | $121.00 | $90.68 | TheFly | Abbott initiated with an Outperform at Baird |
| April 22, 2026 12:25 am | — | Daiwa | $92.00 | $92.75 | TheFly | Abbott downgraded to Neutral from Outperform at Daiwa |
| April 20, 2026 9:47 am | Matt Miksic | Barclays | $143.00 | $96.83 | TheFly | Abbott price target lowered to $143 from $144 at Barclays |
| April 17, 2026 11:52 am | — | UBS | $115.00 | $95.46 | TheFly | Abbott price target lowered to $115 from $132 at Oppenheimer |
Latest News for ABT
Foyston Gordon and Payne Inc purchased a new stake in Abbott Laboratories (NYSE: ABT) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 12,200 shares of the healthcare product maker's stock, valued at approximately $1,107,000. A number of other institutional investors have also recently
EP Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories (NYSE: ABT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 79,164 shares of the healthcare product maker's stock, valued at approximately $7,183,000. A number of other institutional
Daiichi Life Insurance Co. Ltd. purchased a new position in Abbott Laboratories (NYSE: ABT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 99,481 shares of the healthcare product maker's stock, valued at approximately $9,027,000. Several other hedge funds
Clear Harbor Asset Management LLC bought a new stake in Abbott Laboratories (NYSE: ABT) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 53,874 shares of the healthcare product maker's stock, valued at approximately $4,889,000. A number
Forefront Analytics LLC purchased a new stake in Abbott Laboratories (NYSE: ABT) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,665 shares of the healthcare product maker's stock, valued at approximately $514,000. Abbott Laboratories makes up about 0.6% of Forefront Analytics LLC's
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.